June 17, 2025 02:49 PM EDTUpdated 05:47 PM

Orphan drug, PBM changes are excluded from Senate version of Trump tax bill

Zachary Brennan

Senior Editor

The Senate Finance Committee’s version of a massive tax cut package omits some PBM reforms and other provisions from the House-passed version that change how …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Orphan drug, PBM changes are excluded from Senate version of Trump tax bill

Zachary Brennan

Senior Editor

Sign up to read this article for free.

FDA unveils one-year pilot to speed some new drugs to market in just one month

After a quiet year, Xaira unwraps some of its AI research, eyeing a virtual cell

Members of Congress oppose NIH's payment cut plan, urge appeals court to maintain block

Lilly to bolster gene editing pipeline, buying Verve for up to $1.3B

Dyne pivots on primary endpoint, delays filing for DM1 drug

This company has spent a decade innovating NGS-based companion diagnostics worldwide–what’s next?

Or­phan drug, PBM changes are ex­clud­ed from Sen­ate ver­sion of Trump tax bill

Zachary Brennan

Senior Editor

Sign up to read this article for free.

FDA un­veils one-year pi­lot to speed some new drugs to mar­ket in just one month

Af­ter a qui­et year, Xaira un­wraps some of its AI re­search, eye­ing a vir­tu­al cell

Mem­bers of Con­gress op­pose NI­H's pay­ment cut plan, urge ap­peals court to main­tain block

Lil­ly to bol­ster gene edit­ing pipeline, buy­ing Verve for up to $1.3B

Dyne piv­ots on pri­ma­ry end­point, de­lays fil­ing for DM1 drug

This com­pa­ny has spent a decade in­no­vat­ing NGS-based com­pan­ion di­ag­nos­tics world­wide–what’s next?

Orphan drug, PBM changes are excluded from Senate version of Trump tax bill

FDA unveils one-year pilot to speed some new drugs to market in just one month

After a quiet year, Xaira unwraps some of its AI research, eyeing a virtual cell

Members of Congress oppose NIH's payment cut plan, urge appeals court to maintain block

Lilly to bolster gene editing pipeline, buying Verve for up to $1.3B

Dyne pivots on primary endpoint, delays filing for DM1 drug

This company has spent a decade innovating NGS-based companion diagnostics worldwide–what’s next?